Ad­vo­ca­cy groups don't want Janet Wood­cock to head the FDA, blast­ing ‘reg­u­la­to­ry fail­ures’ in opi­oid cri­sis

It turns out the con­tro­ver­sies around Janet Wood­cock’s reg­u­la­to­ry lega­cy weren’t lim­it­ed to Sarep­ta’s eteplirsen.

A coali­tion of ad­vo­ca­cy groups ded­i­cat­ed to the opi­oid cri­sis urged Nor­ris Cochran and Xavier Be­cer­ra — the act­ing and des­ig­nat­ed HHS sec­re­tary, re­spec­tive­ly — to keep her reign as in­ter­im FDA chief a “very short tran­si­tion.” Dur­ing her lengthy tenure as CDER, they add, Wood­cock presided over “one of the worst reg­u­la­to­ry agency fail­ures in U.S. his­to­ry.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER